Lycia Therapeutics, Inc.

Lycia Therapeutics, Inc. publicly filed a registration statement on Form S-1 on Oct 5, 2026 for a proposed initial public offering on Nasdaq Global Market, and has not yet priced. Underwriters named in the filing: Jefferies, TD Cowen, Evercore ISI and Guggenheim.

Lycia Therapeutics, Inc. is a clinical-stage biotechnology company using its LYTAC platform to degrade disease-causing extracellular proteins, initially for autoimmune, inflammatory and allergic diseases. Its lead candidate LCA-0061 targets IgE for allergic diseases including food allergy and is in a Phase 1 trial.

Status

Filed, not priced

Exchange

Nasdaq Global Market

First filed

Oct 5, 2026

Latest amendment

Oct 5, 2026

Underwriters

Jefferies, TD Cowen, Evercore ISI and Guggenheim

Sector

Biotech & pharma

Country / state

CA